Dec 12, 2024
In this episode, host Shikha Jain, MD, speaks
with David Gandara, MD, about how ctDNA and CAR-T
cell therapies are transforming precision medicine, the importance
of patient reported outcomes and more.
• Welcome to another exciting episode of Oncology
Overdrive 0:14
• About Gandara 0:19
• The interview 1:02
• Can you tell me a little more about what you are
working on now? 1:25
• How did you get engaged with the community in
Hawaii? 6:30
• What do you think is going to happen with ctDNA
moving forward? 8:29
• Can you utilize ctDNA and minimal residual disease
information to determine how long patients need to be on adjuvant
therapy? 11:42
• How did you get into the ctDNA space?
15:06
• How do you see AI transforming health care beyond
providing patients with more information and taking more ownership
of their health? 18:28
• Can you tell us more about how a second opinion
clinic works? How did this type of clinic develop and become part
of what you do? 23:17
• What are some of your predictions as to what will
happen in oncology care over the next ten to twenty years?
29:00
• If someone could only listen to the last few minutes
of this episode, what would you want listeners to take away?
37:30
• How to contact Gandara
38:47
• Thanks for listening
39:10
David Gandara, MD, is a clinician-scientist and
lung cancer specialist internationally recognized for his expertise
in thoracic cancers, cancer drug development and biomarker
development.
We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.
Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine.